Abstract
Background Drug-resistant focal epilepsy is often caused by focal cortical dysplasia (FCD). The impact of FCD location on clinical presentation and surgical outcome is largely unknown. We created a large neuroimaging cohort of patients with individually mapped FCDs to determine predictors of lesion location and postsurgical seizure freedom to aid presurgical decision-making.
Methods The Multi-centre Epilepsy Lesion Detection (MELD) project collated a retrospective cohort of 580 patients with epilepsy due to FCD from 20 epilepsy centres worldwide. MRI-based maps of individual FCD lesions with accompanying demographic, clinical and surgical information were collected for each patient. We mapped the distribution of FCD lesions across the cerebral cortex and examined for associations between clinical factors and lesion location.
Findings FCDs were non-uniformly distributed across the brain, concentrating in the superior frontal sulcus, frontal pole and temporal pole. Age of epilepsy onset was typically before age 10. Earlier epilepsy onset was associated with lesions in primary sensory areas while later epilepsy onset was associated with lesions in association cortices. Lesions in temporal and occipital lobes tended to be larger than frontal lobe lesions. Seizure freedom rates varied with FCD location, being around 30% in visual, motor and premotor areas to 75% in superior temporal and frontal gyri. These differences are likely attributable to reduced resection volumes due to neurosurgical caution around eloquent cortex.
Interpretation The MELD project has gathered the largest neuroimaging cohort of patients with FCD to date. The location of the FCD is non-uniformly distributed across the cerebral cortex and is an important determinant of its size, the age of epilepsy onset and the likelihood of seizure freedom post-surgery. Using an open-science collaborative initiative, we have characterised the spatial distribution of a focal pathology to identify data-driven, patient-specific predictors of lesion location and postsurgical seizure freedom to inform clinical decision-making.
Funding Rosetrees Trust
Evidence before this study To identify previous research on lesion location and surgical outcome in FCD, we searched PubMed using the terms “focal cortical dysplasia” OR “FCD”, AND “location” OR “lobe”, AND “outcome”. The search was for full manuscripts from database inception until 24 November 2020 without language restrictions and yielded 307 results. Only five papers had sample sizes of over 200 patients with focal cortical dysplasia. All five studies found that temporal resections are associated with better postsurgical seizure freedom. However, four of these studies limit lesion localisation to temporal and extra-temporal, with none describing lesion location beyond coarse lobar categorisations.
Added value of this study This is the first study to map the distribution of FCD lesion locations across the cerebral cortex in a large cohort of patients, and provide a 3D probability map of the non-uniform distribution of lesions across the cerebral cortex. We demonstrate that the location of a FCD is significantly associated with age of epilepsy onset and is a predictor of postoperative seizure freedom. Our openly available methodological developments provide novel tools for linking focal neurological abnormalities to their clinical presentation and subsequent surgical outcome.
Implications of all the available evidence Neuroimaging of patients with drug-resistant epilepsy should be carefully reviewed by radiologists to look for structural aetiologies, such as FCD, which are amenable to surgery. As our study showed FCDs are non-uniformly distributed across the cerebral cortex, our probability map can help radiologists in the clinical search for FCDs, which can be subtle lesions. Lesion location is significantly associated with age of epilepsy onset and post-operative seizure freedom. Individualised, patient-specific predictors of lesion location and surgical outcome will ultimately improve the diagnosis, prognosis and treatment of patients with complex neurological conditions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.protocols.io/researchers/meld-project
Funding Statement
The MELD project is supported by the Rosetrees Trust (A2665). This work is supported by the NIHR GOSH BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. KSW is supported by the Wellcome Trust (215901/Z/19/Z). XY, NYC & WDG were supported by the Hess Foundation. FC and CY were supported by the Sao Paulo Research Foundation (FAPESP), Grant # 2013/07559-3 (BRAINN - Brazilian Institute of Neuroscience and Neurotechnology). JOM is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 206675/Z/17/Z) and received support from the Medical Research Council Centre for Neurodevelopmental Disorders, King's College London (grant MR/N026063/1). PEV is a Fellow of MQ: Transforming Mental Health (MQF17_24) and of the Alan Turing Institute funded by EPSRC grant EP/N510129/1. JJM and KZ are funded by the National Natural Science Foundation of China (No. 82071457). PS acknowledges the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). GW is supported by the MRC (G0802012, MR/MR00841X/1). KJW is supported by The Alan Turing Institute under the EPSRC grant EP/N510129/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCL Great Ormond Street Institute of Child Health (leading the study) received approval from the NHS Health Research Authority to conduct this study on anonymised data. The study involved the sharing of anonymised patient data from each of the contributing epilepsy centres. Each individual centre received approval from their local institutional review board or ethics committee to share the anonymised data with the study coordinators.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code to reproduce all analyses and figures in this manuscript is available to download from github.com/MELDproject. Requests can be made for access to the full MELD dataset.
